ES2147553T5 - Vectores virales recombinantes para la expresion en unas celulas musculares. - Google Patents
Vectores virales recombinantes para la expresion en unas celulas musculares.Info
- Publication number
- ES2147553T5 ES2147553T5 ES92921684T ES92921684T ES2147553T5 ES 2147553 T5 ES2147553 T5 ES 2147553T5 ES 92921684 T ES92921684 T ES 92921684T ES 92921684 T ES92921684 T ES 92921684T ES 2147553 T5 ES2147553 T5 ES 2147553T5
- Authority
- ES
- Spain
- Prior art keywords
- vectors
- muscle cells
- treatment
- cells
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000000663 muscle cell Anatomy 0.000 title claims abstract description 20
- 230000014509 gene expression Effects 0.000 title claims abstract description 13
- 239000013603 viral vector Substances 0.000 title description 4
- 239000013598 vector Substances 0.000 claims abstract description 32
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 17
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 17
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 17
- 238000003780 insertion Methods 0.000 claims abstract description 10
- 230000037431 insertion Effects 0.000 claims abstract description 10
- 229920001184 polypeptide Polymers 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000002773 nucleotide Substances 0.000 claims abstract description 8
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 230000007170 pathology Effects 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 5
- 108010069091 Dystrophin Proteins 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 230000002537 thrombolytic effect Effects 0.000 claims description 3
- 108091023040 Transcription factor Proteins 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 description 15
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 102000005936 beta-Galactosidase Human genes 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000010276 construction Methods 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101150102264 IE gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9111947 | 1991-09-27 | ||
| FR9111947A FR2681786A1 (fr) | 1991-09-27 | 1991-09-27 | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2147553T3 ES2147553T3 (es) | 2000-09-16 |
| ES2147553T5 true ES2147553T5 (es) | 2004-11-16 |
Family
ID=9417378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92921684T Expired - Lifetime ES2147553T5 (es) | 1991-09-27 | 1992-09-25 | Vectores virales recombinantes para la expresion en unas celulas musculares. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0559884B2 (https=) |
| JP (1) | JP3487597B2 (https=) |
| AT (1) | ATE192500T1 (https=) |
| AU (1) | AU666142B2 (https=) |
| CA (1) | CA2097185C (https=) |
| DE (1) | DE69230993T3 (https=) |
| DK (1) | DK0559884T4 (https=) |
| ES (1) | ES2147553T5 (https=) |
| FR (1) | FR2681786A1 (https=) |
| GR (1) | GR3034094T3 (https=) |
| SG (1) | SG49081A1 (https=) |
| WO (1) | WO1993006223A1 (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5538722A (en) * | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
| WO1994010322A1 (en) * | 1992-10-29 | 1994-05-11 | Board Of Regents, The University Of Texas System | Adenovirus-mediated ldl receptor gene transfer and targeting |
| JPH08506008A (ja) * | 1992-11-18 | 1996-07-02 | アーチ ディベロプメント コーポレイション | 心筋及び血管平滑筋へのアデノウィルス介在遺伝子移入 |
| FR2705361B1 (fr) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US6133028A (en) * | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| US6140087A (en) * | 1993-06-24 | 2000-10-31 | Advec, Inc. | Adenovirus vectors for gene therapy |
| US5919676A (en) * | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
| ES2249761T3 (es) * | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| US6120764A (en) * | 1993-06-24 | 2000-09-19 | Advec, Inc. | Adenoviruses for control of gene expression |
| US6730507B1 (en) | 1993-06-24 | 2004-05-04 | Merck & Co., Inc. | Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration |
| US7045347B2 (en) | 1993-06-24 | 2006-05-16 | Advec, Inc. | Helper dependent adenovirus vectors based on integrase family site-specific recombinases |
| US6080569A (en) | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
| US20020136708A1 (en) | 1993-06-24 | 2002-09-26 | Graham Frank L. | System for production of helper dependent adenovirus vectors based on use of endonucleases |
| BR9405507A (pt) * | 1993-07-13 | 1999-05-25 | Rhone Poulenc Rorer Sa | Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica |
| FR2707664B1 (fr) * | 1993-07-13 | 1995-09-29 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| FR2718749B1 (fr) * | 1994-04-18 | 1996-05-31 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| FR2712812B1 (fr) * | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| US6379943B1 (en) | 1999-03-05 | 2002-04-30 | Merck & Co., Inc. | High-efficiency Cre/loxp based system for construction of adenovirus vectors |
| US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| WO1996026742A1 (en) | 1995-02-28 | 1996-09-06 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
| US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
| US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| US6974694B2 (en) | 1995-06-07 | 2005-12-13 | Advec, Inc. | Adenoviruses for control of gene expression |
| US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US5837534A (en) * | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
| US5866552A (en) * | 1996-09-06 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Method for expressing a gene in the absence of an immune response |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| HUP0004589A3 (en) | 1997-06-30 | 2003-08-28 | Centre Nat Rech Scient | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
| US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| CN1263854C (zh) | 1997-11-06 | 2006-07-12 | 启龙股份公司 | 奈瑟球菌抗原 |
| AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
| JP2002502608A (ja) | 1998-02-06 | 2002-01-29 | コラテラル・セラピューティックス・インコーポレイテッド | 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体 |
| EP2261352A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| JP2002527066A (ja) | 1998-10-15 | 2002-08-27 | カイロン コーポレイション | 転移性乳癌および結腸癌調節遺伝子 |
| US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| AU2367600A (en) | 1998-12-16 | 2000-07-03 | Chiron Corporation | Human cyclin-dependent kinase ((hpnqalre)) |
| US6673601B1 (en) | 1999-04-15 | 2004-01-06 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
| EP1721982B1 (en) | 1999-04-15 | 2013-04-10 | Boehringer Ingelheim Vetmedica GmbH | Chimeric lyssavirus nucleic acids and polypeptides |
| JP2003518363A (ja) | 1999-04-30 | 2003-06-10 | カイロン エセ．ピー．アー． | 保存されたナイセリア抗原 |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| RU2281956C2 (ru) | 1999-10-29 | 2006-08-20 | Чирон С.Р.Л. | Антигенные пептиды neisseria |
| PT2289545T (pt) | 2000-01-17 | 2016-09-06 | Glaxosmithkline Biologicals Sa | Vacina de omv suplementada contra meningococos |
| ES2281409T3 (es) | 2000-02-28 | 2007-10-01 | Novartis Vaccines And Diagnostics S.R.L. | Expresion heterologa de proteinas de neisseria. |
| US7238672B1 (en) | 2000-04-17 | 2007-07-03 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
| EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
| EP1191104A1 (en) * | 2000-09-26 | 2002-03-27 | Introgene B.V. | Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine |
| KR20030042003A (ko) * | 2000-10-06 | 2003-05-27 | 가부시키가이샤 디나벡크 겐큐쇼 | 골격근에 외래유전자를 도입하기 위한 파라믹소바이러스 벡터 |
| DK1328543T3 (da) | 2000-10-27 | 2009-11-23 | Novartis Vaccines & Diagnostic | Nukleinsyrer og proteiner fra streptococcus-gruppe A & B |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| FR2829136B1 (fr) | 2001-08-29 | 2006-11-17 | Aventis Pharma Sa | Derives lipidiques d'aminoglycosides |
| CN100515494C (zh) | 2001-12-12 | 2009-07-22 | 启龙有限公司 | 抗沙眼衣原体的免疫 |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| US8268324B2 (en) | 2004-03-29 | 2012-09-18 | Galpharma Co., Ltd. | Modified galectin 9 proteins and use thereof |
| US8563511B2 (en) | 2004-10-06 | 2013-10-22 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| EP1856526A4 (en) | 2005-01-20 | 2008-11-12 | Univ Rochester | THIOREDOXIN-INTERACTING PROTEIN (TXNIP) AS REGULATOR OF VASCULAR FUNCTION |
| US8026354B2 (en) | 2005-11-23 | 2011-09-27 | Institut Pasteur | Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
| DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
| EP2139447A2 (en) | 2007-03-20 | 2010-01-06 | Harold Brem | Gm-csf cosmeceutical compositions and methods of use thereof |
| US8790664B2 (en) | 2008-09-05 | 2014-07-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Multimodular assembly useful for intracellular delivery |
| US8772238B2 (en) | 2009-03-18 | 2014-07-08 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer |
| CA3239368A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| EP2658567A4 (en) | 2010-12-28 | 2014-09-24 | Univ Rochester | METHOD FOR MODIFYING INSULIN SIGNAL TRANSMISSION BY BILIVERDINREDUCTASE (BVR) AND BVR-DERIVED PEPTIDES |
| US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
| EP2908853B1 (en) | 2012-10-21 | 2018-12-05 | University Of Rochester | Thy1 (cd90) as a therapy to control adipose tissue accumulation |
| WO2014176259A1 (en) | 2013-04-22 | 2014-10-30 | Icahn School Of Medicine At Mount Sinai | Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis |
| US11273151B2 (en) | 2015-11-04 | 2022-03-15 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
| US11246868B2 (en) | 2016-04-26 | 2022-02-15 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL76751A (en) * | 1984-11-01 | 1991-04-15 | American Home Prod | Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies |
| FR2573436B1 (fr) * | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| DE3751664T2 (de) * | 1986-08-01 | 1996-06-05 | Commw Scient Ind Res Org | Rekombinanter impfstoff |
| ES2116269T3 (es) * | 1989-03-21 | 1998-07-16 | Vical Inc | Expresion de secuencias exogenas de polinucleotidos en un vertebrado. |
| WO1990013640A1 (en) * | 1989-05-01 | 1990-11-15 | The University Of Notre Dame Du Lac | Methods and materials for expression of human plasminogen in a eukaryotic cell system |
| GB9001766D0 (en) * | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
-
1991
- 1991-09-27 FR FR9111947A patent/FR2681786A1/fr active Granted
-
1992
- 1992-09-25 JP JP50585393A patent/JP3487597B2/ja not_active Expired - Lifetime
- 1992-09-25 AU AU27902/92A patent/AU666142B2/en not_active Expired
- 1992-09-25 CA CA002097185A patent/CA2097185C/fr not_active Expired - Lifetime
- 1992-09-25 SG SG1996005855A patent/SG49081A1/en unknown
- 1992-09-25 ES ES92921684T patent/ES2147553T5/es not_active Expired - Lifetime
- 1992-09-25 DK DK92921684T patent/DK0559884T4/da active
- 1992-09-25 EP EP92921684A patent/EP0559884B2/fr not_active Expired - Lifetime
- 1992-09-25 WO PCT/FR1992/000898 patent/WO1993006223A1/fr not_active Ceased
- 1992-09-25 AT AT92921684T patent/ATE192500T1/de active
- 1992-09-25 DE DE69230993T patent/DE69230993T3/de not_active Expired - Lifetime
-
2000
- 2000-08-02 GR GR20000401791T patent/GR3034094T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2681786A1 (fr) | 1993-04-02 |
| FR2681786B1 (https=) | 1995-05-12 |
| DK0559884T3 (da) | 2000-10-02 |
| EP0559884B1 (fr) | 2000-05-03 |
| DE69230993D1 (de) | 2000-06-08 |
| GR3034094T3 (en) | 2000-11-30 |
| SG49081A1 (en) | 1998-05-18 |
| WO1993006223A1 (fr) | 1993-04-01 |
| ES2147553T3 (es) | 2000-09-16 |
| CA2097185A1 (fr) | 1993-03-28 |
| JPH06502771A (ja) | 1994-03-31 |
| AU666142B2 (en) | 1996-02-01 |
| ATE192500T1 (de) | 2000-05-15 |
| EP0559884A1 (fr) | 1993-09-15 |
| DK0559884T4 (da) | 2004-08-02 |
| EP0559884B2 (fr) | 2004-04-07 |
| AU2790292A (en) | 1993-04-27 |
| DE69230993T3 (de) | 2004-12-16 |
| JP3487597B2 (ja) | 2004-01-19 |
| CA2097185C (fr) | 2007-07-24 |
| DE69230993T2 (de) | 2000-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2147553T5 (es) | Vectores virales recombinantes para la expresion en unas celulas musculares. | |
| Tripathy et al. | Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. | |
| ES2264123T3 (es) | Adenovirus recombinantes defectivos para la terapia genica de tumores. | |
| ES2466415T3 (es) | Construcción de recombinante de adenovirus oncolítico que expresa específicamente el factor inmunomodulador GM-CSF en células tumorales y usos del mismo | |
| ES2401608T3 (es) | Blastocitos CD34 mesenquimales para uso en terapia génica de diabetes | |
| Lesbordes et al. | In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice | |
| ES2288993T3 (es) | Distribucion de factores angiogenicos mediada por virus adenoasociados. | |
| US6685934B1 (en) | Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF) | |
| JP2004313198A (ja) | 心筋及び血管平滑筋へのアデノウイルス介在遺伝子移入 | |
| Byun et al. | Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector | |
| WO2024207617A1 (zh) | 重编程因子抗衰老mRNA组合物、制备方法及应用 | |
| EA005157B1 (ru) | Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов | |
| US20040224409A1 (en) | Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) | |
| ES2425321T3 (es) | Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos | |
| US6743623B2 (en) | Viral recombinant vectors for expression in muscle cells | |
| Rowland et al. | Potential gene therapy strategies in the treatment of cardiovascular disease | |
| JP2001523106A (ja) | 真核遺伝子発現カセットおよびその使用 | |
| ES2361659T3 (es) | PROCEDIMIENTOS ÚTILES PARA LA MODULACIÓN DE LA ANGIOGÉNESIS QUE UTILIZAN LA TIROSINA CINASA Src. | |
| Castro | Gene therapy strategies for the treatment of pituitary tumours | |
| Kaneda | Improvements in gene therapy technologies | |
| US6099831A (en) | Viral recombinant vectors for expression in muscle cells | |
| Baum et al. | The mouth is a gateway to the body: gene therapy in 21st century dental practice | |
| Coutelle et al. | Liposomes and viruses for gene therapy of cystic fibrosis | |
| Feuerbach et al. | Progress in human gene therapy | |
| Kurachi et al. | Gene therapy by myoblast-mediated gene transfer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 559884 Country of ref document: ES |